Black Rock Inc. Avadel Pharmaceuticals PLC Transaction History

Black Rock Inc.

$4.23 Trillion
Q1 2024

A detailed history of Black Rock Inc. transactions in Avadel Pharmaceuticals PLC stock. As of the latest transaction made, Black Rock Inc. holds 76,442 shares of AVDL stock, worth $1.09 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

76,442

Previous 81,532 6.24%

Holding current value

$1.09 Million

Previous $1.15 Million 12.16%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	SELL	$12.55 - $17.22 $63,879 - $87,649	-5,090 Reduced 6.24%	76,442 $1.29 Million
Q4 2023 Feb 13, 2024	BUY	$9.64 - $14.59 $29,373 - $44,455	3,047 Added 3.88%	81,532 $1.15 Million
Q3 2023 Nov 13, 2023	BUY	$10.3 - $15.99 $258,540 - $401,364	25,101 Added 47.02%	78,485 $808,000
Q2 2023 Aug 11, 2023	BUY	$8.48 - $16.48 $52,448 - $101,928	6,185 Added 13.1%	53,384 $879,000
Q1 2023 May 12, 2023	BUY	$6.41 - $9.95 $56,927 - $88,365	8,881 Added 23.18%	47,199 $432,000

Q4 2022 Feb 13, 2023	BUY	$5.73 - $10.0 $24,346 - $42,490	4,249 Added 12.47%	38,318 $274,000
Q3 2022 Nov 14, 2022	BUY	$2.57 - $7.31 $13,618 - $38,735	5,299 Added 18.42%	34,069 $171,000
Q2 2022 Aug 12, 2022	SELL	$1.07 - $6.95 $8,491 - $55,155	-7,936 Reduced 21.62%	28,770 $70,000
Q1 2022 May 12, 2022	BUY	$5.46 - $8.29 $37,029 - $56,222	6,782 Added 22.66%	36,706 $251,000
Q4 2021 Feb 10, 2022	BUY	$7.34 - $11.18 $66 - $100	9 Added 0.03%	29,924 $242,000
Q3 2021 Nov 09, 2021	BUY	$6.49 - $9.91 $34,637 - $52,889	5,337 Added 21.71%	29,915 $293,000
Q2 2021 Aug 11, 2021	BUY	$6.73 - $9.05 $165,409 - $222,430	24,578 New	24,578 $165,000

Others Institutions Holding AVDL

# of Institutions

133

Shares Held

68.4M

Call Options Held

1.01M

Put Options Held

2.03M

View Full List

About AVADEL PHARMACEUTICALS PLC

Ticker AVDL
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 60,581,300
Market Cap $866M
Description
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and...

More about AVDL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.

Account